Skip to main content

Table 1 Patient characteristics

From: 5-year outcomes of salvage endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma

Patient #

Age at surgery / Gender

Ethnicity

cTNM

cStage

WHO classd

Time of diagnosisa

Initial treatment

Open procedure / Timeb

Follow-upc (months)

P1

61.9 / M

Caucasian

T2N2M0

Stage 3

III

24.4

60 Gy to nasopharynx

No

56.4

P2

50.3 / M

Taiwanese

T1N2M0

Stage 3

III

48.5

70 Gy to nasopharynx, 50 Gy to neck + chemo (5-FU, cisplatin)

No

57.2

P3

45.8 / M

Chinese

T1N0M0

Stage 1

II

36.2

IMRT (70 Gy to nasopharynx, 54 Gy to neck)

No

70.7

P4

60.4 / F

Japanese

T2N1M0

Stage 2

II

54.2

IMRT (70 Gy) + Chemo (cisplatin, 5-FU)

Yes / 36.7

70.5

P5

60.4 / M

African American

T1N0M0

Stage 1

III

5.2

IMRT (70 Gy to nasopharynx, 54 Gy to neck)

No

94.9

P6

80.8 / F

Chinese

T1N0M0

Stage 1

III

13.1

IMRT (70 Gy)

No

93.6

P7

34.9 / F

Taiwanese

T3N1M0

Stage 3

II

24.8

IMRT (70 Gy) + Chemo (cisplatin, 5-FU, bevacizumab)

No

89.1

P8

70.5 / M

Taiwanese

T3N0M0

Stage 3

III

168

External beam radiation

Yes / 86.8

96

P9

63.8 / M

Filipino

T1N1M0

Stage 2

III

24.0

IMRT (66.6 Gy to nasopharynx, 59.4 Gy to neck) + Chemo (cisplatin)

No

86

P10

69.9 / M

Filipino

T1N1M0

Stage 2

II

13.0

IMRT (70 Gy to nasopharynx, 56.4 Gy to neck)

No

67.2

P11

42.5 / M

Chinese

T1N3M0

Stage 4a

III

84.7

70 Gy to nasopharynx, 72 Gy to neck + Chemo (5-FU, cisplatin)

Yes / 36.4

60.6

P12

45.5 / M

Chinese

T1N2M0

Stage 3

III

4.2

IMRT (70 Gy) + Chemo (5-FU, cisplatin)

No

82.2

P13

44.6 / F

Chinese

T1N2M0

Stage 3

I

156

Radiation + Chemo

Yes / 145

78.2

  1. a“Time of diagnosis” of the presenting nasopharyngeal carcinoma is denoted by the number of months the diagnosis was made prior to the first endoscopic nasopharyngectomy
  2. b“Time” of open nasopharyngectomy is denoted by the number of months the procedure was performed prior to the first endoscopic nasopharyngectomy
  3. c“Follow-up” is calculated as the number of months of patient follow-up after the first endoscopic nasopharyngectomy
  4. dTumor classifications: I = keratinizing, II = non-keratinizing, III = undifferentiated, non-keratinizing, associated with EBV